Investing.com - U.S. pharmaceutical giant Pfizer reported better-than-expected fourth quarter earnings and revenue figures ahead of Tuesday’s opening bell.
Pfizer said adjusted earnings per share came in at USD0.56 during the fourth quarter, above expectations for earnings of USD0.52 per share. The company’s fourth quarter revenue totaled USD13.56 billion, surpassing forecasts for revenue of USD13.37 billion.
Pfizer said it expected adjusted full-year earnings to come in at a range between USD2.20 to USD2.30 per share, compared to expectations for earnings of USD2.28 per share.
Ian Read, Chairman and Chief Executive Officer, stated, “We enter 2014 with confidence in the competitive positioning of our commercial businesses, the prospects for our recently launched products and the strength of our research pipeline.”
Following the release of the report, Pfizer shares rose 2% in pre-market trade.
Meanwhile, the outlook for U.S. equity markets was mixed. The Dow Jones Industrial Average futures indicated a gain of 0.6% at the open, S&P 500 futures pointed to a rise of 0.45%, while Nasdaq 100 futures dipped 0.35% ahead of the open.